KalVista Pharmaceuticals Reports Strong Early Performance for EKTERLY with $50M Revenue in Six Months
KalVista Pharmaceuticals reported nearly $50 million in revenue for its drug EKTERLY within six months of launch, reaching over 20% of patients. The company also announced plans for an NDA filing and has $300 million in cash reserves, indicating strong financial positioning.
Tickers: $KALV
Topics: EKTERLY HAE treatment pharmaceuticals product launch revenue